Enquiries about Vivli Member Studies
English
Canada, Toronto
Vivli
数据描述

The dataset is a collection of Vivli member study listings and related access information, covering studies available through the Vivli Platform as well as guidance for enquiring about studies not yet listed. It contains study-level availability details, instructions for submitting enquiries or data access requests, account requirements for platform use, and notes on member-specific submission processes and response discretion. Its purpose is to support researchers and other users in identifying relevant clinical study data, obtaining additional study information, and requesting access to shared datasets, while reflecting member policies such as limits on sharing studies before primary completion.
vivli.org
IP: 162.159.135.42
加载中...
相关论文
29Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
Sandro Pignata•Amit Oza•Geoff Hall•Beatriz Pardo•Radoslaw Madry等 20 人
British Journal Of Cancer
2025
•2025/3/17
•00 p.1-8
The open-label, single-arm, multicentre ORZORA trial (NCT02476968) evaluated maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) with a germline (g) or somatic (s) BRCA1 and/or BRCA2 mutation (BRCAm) or a non-BRCA homologous recombination repair mutation (non-BR...
Medical researchOncology
10.1038/S41416-025-02966-X
ISSN:0007-0920
Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial
Shabir A. Madhi•Hasra Snaggs•Zahra Skogeby•Ye Feng•Shaun Barnabas等 18 人
Nature Medicine
2026
•2026/7/28
•00 p.1-12
Group B Streptococcus (GBS) disease is a major cause of infant morbidity and mortality. Capsular polysaccharide conjugate GBS vaccines have been evaluated for decades; however, none is licensed. This phase 1/2 trial evaluated an investigational maternal hexavalent polysaccharide−protein conjugate GB...
Bacterial infectionDiseasesPaediatricsVaccines
10.1038/S41591-026-04558-5
ISSN:1078-8956
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Neil H. Segal•Ignacio Melero•Victor Moreno•Neeltje Steeghs•Aurelien Marabelle等 24 人
Nature Communications
2024
•2024/5/15
•Vol.15 No.1 p.1-14
Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label Phase 1 dose-escalation and -expansion studies: as a single...
Antibody therapyCancer immunotherapyColon cancer
10.1038/S41467-024-48479-8
ISSN:2041-1723
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer
Popat Sanjay•Liu Stephen V.•Scheuer Nicolas•Hsu Grace G.•Lockhart Alexandre等 8 人
Nature Communications
2022
•2022/6/17
•Vol.13 No.1 p.1-10
As advanced non-small cell lung cancer (aNSCLC) is being increasingly divided into rare oncogene-driven subsets, conducting randomised trials becomes challenging. Using real-world data (RWD) to construct control arms for single-arm trials provides an option for comparative data. However, non-randomi...
Lung cancerNon-small-cell lung cancerOutcomes research
10.1038/S41467-022-30908-1
ISSN:2041-1723
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Wilkins Deidre•Yuan Yuan•Chang Yue•Aksyuk Anastasia A.•Núñez Beatriz Seoane等 11 人
Nature Medicine
2023
•2023/4/24
•00 p.1-8
Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and full-term infants in the phase 2b and phase 3 MELODY trials. We analyzed serum samples collected from 2,143 infant...
ImmunizationVaccinesViral infection
10.1038/S41591-023-02316-5
ISSN:1078-8956
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck•Eva Ciruelos•Guy Jerusalem•Volkmar Müller•Naoki Niikura等 22 人
Nature Medicine
2024
•2024/9/13
•00 p.1-10
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases...
Breast cancer
10.1038/S41591-024-03261-7
ISSN:1078-8956
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Benkeser David•Fong Youyi•Janes Holly E.•Kelly Elizabeth J.•Hirsch Ian等 40 人
Npj Vaccines
2023
•2023/3/11
•Vol.8 No.1 p.1-13
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two doses were assessed as correlates of risk and protection aga...
Adaptive immunityInfectious diseasesVaccinesViral infection
10.1038/S41541-023-00630-0
ISSN:2059-0105
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Chmielecki Juliann•Mok Tony•Wu Yi-Long•Han Ji-Youn•Ahn Myung-Ju等 16 人
Nature Communications
2023
•2023/2/27
•Vol.14 No.1 p.1-8
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with EGFR T790M ad...
CancerLung cancerTargeted therapies
10.1038/S41467-023-35962-X
ISSN:2041-1723
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
Bardia Aditya•Chandarlapaty Sarat•Linden Hannah M.•Ulaner Gary A.•Gosselin Alice等 17 人
Nature Communications
2022
•2022/7/15
•Vol.13 No.1 p.1-15
AMEERA-1 is a Phase 1/2 open-label single-arm study evaluating once-daily (QD) amcenestrant, an orally bioavailable selective estrogen receptor (ER) degrader, in postmenopausal women with ER+/HER2− advanced breast cancer (NCT03284957), who were mostly heavily pretreated (including targeted therapies...
Breast cancerCancer genomicsCancer therapeutic resistance
10.1038/S41467-022-31668-8
ISSN:2041-1723
A machine learning approach to population pharmacokinetic modelling automation
Sam Richardson•Itziar Irurzun Arana•Andrzej Nowojewski•Diansong Zhou•Jacob Leander等 8 人
Communications Medicine
2025
•2025/7/31
•Vol.5 No.1 p.1-10
Population pharmacokinetic (PopPK) models are crucial for understanding drug behaviour across populations, yet traditional development is often labour-intensive and slow. This study demonstrates an automated, out-of-the-box approach for popPK model development, leveraging optimisation algorithms imp...
Clinical pharmacologyPharmacokinetics
10.1038/S43856-025-01054-8
ISSN:2730-664X
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial
Tina Cascone•Laura Bonanno•Florian Guisier•Amelia Insa•Moishe Liberman等 25 人
Nature Medicine
2025
•2025/5/31
•00 p.1-9
In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (...
ImmunotherapyNon-small-cell lung cancer
10.1038/S41591-025-03746-Z
ISSN:1078-8956
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Salvatore Siena•Kanwal Raghav•Toshiki Masuishi•Kensei Yamaguchi•Tomohiro Nishina等 19 人
Nature Communications
2024
•2024/11/25
•Vol.15 No.1 p.1-12
DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). The present exploratory biomarker analy...
CancerPredictive markersTargeted therapies
10.1038/S41467-024-53223-3
ISSN:2041-1723
Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home
Ravi Jhaveri•Neil Skolnik•Allyn Bandell
Npj Vaccines
2025
•2025/11/23
0In the United States, influenza vaccination coverage in adults and children remains below target, with disparities across racial and ethnic groups and setting urbanicity. Reducing barriers to influenza vaccination may improve coverage. Live attenuated influenza vaccine (LAIV) recently gained United ...
Drug regulationLive attenuated vaccines
10.1038/S41541-025-01324-5
ISSN:2059-0105
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
Melissa L. Johnson•Giulia Fabbri•Carmela Ciardullo•Judy S. Wang•Gerald S. Falchook等 25 人
British Journal Of Cancer
2026
•2026/4/3
•00 p.1-13
Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung cancer (SCLC). Here we report the dose...
Small-cell lung cancerTumour biomarkers
10.1038/S41416-026-03414-0
ISSN:0007-0920
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
Gail D. Lewis•Guangmin Li•Jun Guo•Shang-Fan Yu•Carter T. Fields等 31 人
Nature Communications
2024
•2024/1/11
•Vol.15 No.1 p.1-15
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzumab for binding, conjugated to a reduced potency PBD (pyrrolo...
Breast cancerCancerDrug development
10.1038/S41467-023-44533-Z
ISSN:2041-1723
Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2
Jason P. Laliberte•Yingyun Cai•Tara Kenny•Yi Zhang•Kuishu Ren等 29 人
Npj Vaccines
2025
•2025/12/13
0The COVID-19 pandemic spurred mRNA vaccine innovation, but new SARS-CoV-2 variants highlight the need for vaccines with improved potency and durability. This report presents a novel mRNA vaccine platform encoding virus-like particle antigens (mRNA-VLPs) that mimic native virus structures, aiming to ...
BiotechnologyImmunologyMicrobiology
10.1038/S41541-025-01303-W
ISSN:2059-0105
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Chmielecki Juliann•Gray Jhanelle E.•Cheng Ying•Ohe Yuichiro•Imamura Fumio等 15 人
Nature Communications
2023
•2023/2/27
•Vol.14 No.1 p.1-9
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm ad...
CancerLung cancerTargeted therapies
10.1038/S41467-023-35961-Y
ISSN:2041-1723
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Bahar Ahani•Kevin M. Tuffy•Anastasia A. Aksyuk•Deidre Wilkins•Michael E. Abram等 21 人
Nature Communications
2023
•2023/7/19
•Vol.14 No.1 p.1-10
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season. In this pre-specified analysis, isolat...
AntibodiesBiological therapyPaediatric researchViral infection
10.1038/S41467-023-40057-8
ISSN:2041-1723
Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study
David Price•Maarten J. H. I. Beekman•Walter Javier Mattarucco•Rocio Martina Barriga-Acevedo•Hao-Chien Wang等 11 人
Npj Primary Care Respiratory Medicine
2024
•2024/11/1
•Vol.34 No.1 p.1-10
This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48....
AsthmaHealth policy
10.1038/S41533-024-00397-4
ISSN:2055-1010
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Roy S. Herbst•Thomas John•Christian Grohé•Jonathan W. Goldman•Terufumi Kato等 23 人
Nature Medicine
2025
•2025/3/17
•00 p.1-11
Osimertinib—a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor—is recommended as adjuvant therapy for resected stage IB–IIIA epidermal growth factor receptor-mutated non-small-cell lung cancer, based on significant disease-free survival (DFS) and overall survival improveme...
Lung cancerNon-small-cell lung cancer
10.1038/S41591-025-03577-Y
ISSN:1078-8956
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Takayuki Yoshino•Maria Di Bartolomeo•Kanwal Raghav•Toshiki Masuishi•Fotios Loupakis等 20 人
Nature Communications
2023
•2023/6/7
•Vol.14 No.1 p.1-13
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Pa...
Colorectal cancerMetastasisTargeted therapies
10.1038/S41467-023-38032-4
ISSN:2041-1723
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19
Rhiannon Edge•Sam Matthews•Bahar Ahani•Anastasia A. Aksyuk•Lindsay Clegg等 18 人
Nature Communications
2025
•2025/10/14
•Vol.16 No.1 p.1-14
Clinical development of monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is challenging due to rapid changes in the variant landscape. This study identified a threshold model for neutralising antibody (nAb) titres associated with clinically relevant p...
AntibodiesTranslational researchViral infection
10.1038/S41467-025-63972-4
ISSN:2041-1723
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Neil H. Segal•Jeanne Tie•Scott Kopetz•Michel Ducreux•Eric Chen等 16 人
British Journal Of Cancer
2024
•2024/7/25
•00 p.1-9
To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (...
Cancer immunotherapyColon cancerTumour biomarkers
10.1038/S41416-024-02796-3
ISSN:0007-0920
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Xichun Hu•Qingyuan Zhang•Tao Sun•Huihua Xiong•Wei Li等 24 人
Nature Communications
2025
•2025/5/9
•Vol.16 No.1 p.1-12
In the global CAPItello-291 randomized phase 3 study (NCT04305496) in patients with hormone receptor-positive/HER2-negative advanced breast cancer and progression during/after aromatase inhibitor treatment, capivasertib–fulvestrant significantly improved progression-free survival (PFS) in the overal...
Breast cancerCancer therapyTumour biomarkers
10.1038/S41467-025-59210-6
ISSN:2041-1723
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
Philip N. Newsome•Arun J. Sanyal•Guy Neff•Jörn M. Schattenberg•Vlad Ratziu等 10 人
Nature Communications
2023
•2023/11/6
•Vol.14 No.1 p.1-11
Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver disease with no approved pharmacological treatment. This Phase IIa, double-blind, placebo-controlled, multicentre trial (ClinicalTrials.gov: NCT03166735) investigated pharmacodynamics and safety of BI 1467335, an amine oxidase...
Clinical pharmacologyNon-alcoholic steatohepatitis
10.1038/S41467-023-42398-W
ISSN:2041-1723
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse•Elvire Pons-Tostivint•Keunchil Park•Sylvia Hartl•Patrick M. Forde等 38 人
Nature Medicine
2024
•2024/2/13
•00 p.1-14
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance...
Non-small-cell lung cancerTumour biomarkers
10.1038/S41591-024-02808-Y
ISSN:1078-8956
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine
Holly Janes•Youyi Fong•Ying Huang•David Benkeser•Elizabeth J. Kelly等 31 人
Npj Vaccines
2026
•2026/4/18
0In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were assessed as correlates of risk of severe COVID-19 and Delta ...
DiseasesImmunologyMedical researchMicrobiology
10.1038/S41541-026-01411-1
ISSN:2059-0105
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
Peter Schmid•Seock-Ah Im•Zbigniew Nowecki•Piotr J. Wysocki•Jacek Jassem等 12 人
Nature Cancer
2026
•2026/6/8
•00 p.1-10
More effective therapies are required for advanced breast cancer. We report results from 58 women with locally advanced unresectable or metastatic hormone-receptor (HR)-negative, human epidermal growth factor receptor 2 (HER2)-low breast cancer enrolled in arm 6 of the multicenter, open-label phase ...
Breast cancerCancerDrug developmentTumour biomarkers
10.1038/S43018-026-01181-8
ISSN:2662-1347
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
Princess U. Ogbogu•Florence Roufosse•Praveen Akuthota•Piotr Kuna•Matthieu Groh等 22 人
Nature Medicine
2026
•2026/3/31
•00 p.1-9
Benralizumab, an eosinophil-depleting anti-IL-5 receptor α antibody, has demonstrated efficacy in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and shown promising results in hypereosinophilic syndrome (HES). NATRON was a randomized, double-blind placebo-controlled pha...
ImmunologyMedical research
10.1038/S41591-026-04315-8
ISSN:1078-8956